ID
43686
Descripción
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations; ODM derived from: https://clinicaltrials.gov/show/NCT00148512
Link
https://clinicaltrials.gov/show/NCT00148512
Palabras clave
Versiones (2)
- 20/11/16 20/11/16 -
- 20/9/21 20/9/21 -
Subido en
20 de septiembre de 2021
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Parkinson Disease NCT00148512
Eligibility Parkinson Disease NCT00148512
- StudyEvent: Eligibility
Similar models
Eligibility Parkinson Disease NCT00148512
- StudyEvent: Eligibility
C0030567 (UMLS CUI [2])
C0178602 (UMLS CUI [1,2])
C0439511 (UMLS CUI [1,3])
C0205360 (UMLS CUI [1,4])
C0449238 (UMLS CUI [1,2])
C0332173 (UMLS CUI [1,3])
C1542147 (UMLS CUI [1,2])
C0205494 (UMLS CUI [1,2])
C0205487 (UMLS CUI [1,3])
C0030567 (UMLS CUI [2])
C0497327 (UMLS CUI [3])
C0451306 (UMLS CUI [4])
C0033975 (UMLS CUI [5])
C0270287 (UMLS CUI [6])
C0270288 (UMLS CUI [7])
C0205476 (UMLS CUI [1,2])
C0522055 (UMLS CUI [2])
C0020649 (UMLS CUI [3])
C0740482 (UMLS CUI [4])
C0438215 (UMLS CUI [5])
C1565489 (UMLS CUI [6,1])
C0205082 (UMLS CUI [6,2])
C0205464 (UMLS CUI [1,2])
C0036579 (UMLS CUI [2])
C0003289 (UMLS CUI [3,1])
C1524063 (UMLS CUI [3,2])
C0205272 (UMLS CUI [3,3])
C0242702 (UMLS CUI [4])
C0013227 (UMLS CUI [5,1])
C0242702 (UMLS CUI [5,2])
C0332256 (UMLS CUI [5,3])